Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
bD6LJb8rx9W2uYu4
